144 related articles for article (PubMed ID: 9576639)
1. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.
Cutler NR; Polinsky RJ; Sramek JJ; Enz A; Jhee SS; Mancione L; Hourani J; Zolnouni P
Acta Neurol Scand; 1998 Apr; 97(4):244-50. PubMed ID: 9576639
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease.
Gobburu JV; Tammara V; Lesko L; Jhee SS; Sramek JJ; Cutler NR; Yuan R
J Clin Pharmacol; 2001 Oct; 41(10):1082-90. PubMed ID: 11583476
[TBL] [Abstract][Full Text] [Related]
4. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease.
Sramek JJ; Anand R; Wardle TS; Irwin P; Hartman RD; Cutler NR
Life Sci; 1996; 58(15):1201-7. PubMed ID: 8614273
[TBL] [Abstract][Full Text] [Related]
5. Absorption, metabolism, and disposition of [14C]SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration.
Tse FL; Laplanche R
Pharm Res; 1998 Oct; 15(10):1614-20. PubMed ID: 9794506
[TBL] [Abstract][Full Text] [Related]
6. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans.
Kennedy JS; Polinsky RJ; Johnson B; Loosen P; Enz A; Laplanche R; Schmidt D; Mancione LC; Parris WC; Ebert MH
J Clin Psychopharmacol; 1999 Dec; 19(6):513-21. PubMed ID: 10587286
[TBL] [Abstract][Full Text] [Related]
7. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.
Farlow M; Anand R; Messina J; Hartman R; Veach J
Eur Neurol; 2000; 44(4):236-41. PubMed ID: 11096224
[TBL] [Abstract][Full Text] [Related]
8. Disposition of SDZ ENA 713, an acetylcholinesterase inhibitor, in the rabbit.
Habucky K; Tse FL
Biopharm Drug Dispos; 1998 Jul; 19(5):285-90. PubMed ID: 9673779
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.
Polinsky RJ
Clin Ther; 1998; 20(4):634-47. PubMed ID: 9737824
[TBL] [Abstract][Full Text] [Related]
10. Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients.
Darreh-Shori T; Hellström-Lindahl E; Flores-Flores C; Guan ZZ; Soreq H; Nordberg A
J Neurochem; 2004 Mar; 88(5):1102-13. PubMed ID: 15009666
[TBL] [Abstract][Full Text] [Related]
11. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
Darreh-Shori T; Almkvist O; Guan ZZ; Garlind A; Strandberg B; Svensson AL; Soreq H; Hellström-Lindahl E; Nordberg A
Neurology; 2002 Aug; 59(4):563-72. PubMed ID: 12196650
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor.
Enz A; Boddeke H; Gray J; Spiegel R
Ann N Y Acad Sci; 1991; 640():272-5. PubMed ID: 1776750
[No Abstract] [Full Text] [Related]
13. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type.
Hossain M; Jhee SS; Shiovitz T; McDonald C; Sedek G; Pommier F; Cutler NR
Clin Pharmacokinet; 2002; 41(3):225-34. PubMed ID: 11929322
[TBL] [Abstract][Full Text] [Related]
14. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats.
Kosasa T; Kuriya Y; Matsui K; Yamanishi Y
Eur J Pharmacol; 1999 Sep; 380(2-3):101-7. PubMed ID: 10513568
[TBL] [Abstract][Full Text] [Related]
15. The recovery of cerebrospinal fluid acetylcholinesterase activity in Alzheimer's disease patients after treatment with metrifonate.
Unni L; Vicari S; Moriearty P; Schaefer F; Becker R
Methods Find Exp Clin Pharmacol; 2000; 22(1):57-61. PubMed ID: 10791297
[TBL] [Abstract][Full Text] [Related]
16. Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man.
Holsboer-Trachsler E; Hatzinger M; Stohler R; Hemmeter U; Gray J; Müller J; Kocher R; Spiegel R
Neuropsychopharmacology; 1993 Jan; 8(1):87-92. PubMed ID: 8424849
[TBL] [Abstract][Full Text] [Related]
17. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
18. Rivastigmine. A review of its use in Alzheimer's disease.
Spencer CM; Noble S
Drugs Aging; 1998 Nov; 13(5):391-411. PubMed ID: 9829166
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats.
Kosasa T; Kuriya Y; Matsui K; Yamanishi Y
Eur J Pharmacol; 2000 Feb; 389(2-3):173-9. PubMed ID: 10688981
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
Burns A; Spiegel R; Quarg P
Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
